2020版EAU肾细胞癌诊疗指南更新解读之一——肾脏肿瘤外科治疗新进展  

The update interpretation of 2020 EAU renal cell carcinoma guideline(Part Ⅰ)——progress in surgical treatment of renal cancer

作　　者：郭刚[1] 马鑫[1] Guo Gang;Ma Xin(Department of Urology,The First Medical Center of the PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心泌尿外科,北京100853

出　　处：《中华泌尿外科杂志》2020年第8期575-577,共3页Chinese Journal of Urology

摘　　要：基于近年来最新发表的临床研究结果,欧洲泌尿外科学会(EAU)对其发布的2019版肾细胞癌指南进行了更新,主要涉及肾脏肿瘤的外科治疗、晚期肾细胞癌的免疫治疗及分子靶向治疗等,在肾癌外科治疗方面的更新主要包括:肾血管平滑肌脂肪瘤的手术指征、肾髓质癌的手术指征以及早期肾细胞癌的主动监测与非手术治疗选择等方面。本文将对以上2020版EAU指南中涉及肾脏肿瘤外科治疗的更新内容及其临床意义进行介绍与解读。Based on the latest clinical finding in recent years,the European Association of Urology(EAU)updated the 2019 guideline for renal cell carcinoma,mainly related to surgical treatment of renal tumors,immunotherapy and molecular targeted treatment of metastatic renal cell carcinoma.The updates in the surgical treatment of renal tumor included surgical indication of renal angiomyolipoma and renal medullary carcinoma,the risk of active surveillance and non-surgical treatment of early renal cell carcinoma.This article introduces and interprets the updated content and clinical signification of surgical treatment of renal tumor in EAU guideline 2020.

关 键 词：癌 肾细胞 肾血管平滑肌脂肪瘤 肾髓质癌 主动监测 射频消融 

分 类 号：R737.11[医药卫生—肿瘤]